The College of Medicine

Life Time Appoints James LaValle Chief Science Officer

Retrieved on: 
Monday, April 29, 2024
American Academy, Organization, University, Lavalle, Book, University of Cincinnati, Health, Étienne-Émile Baulieu, LTH, Weight loss, Partnership, Research, Obesity, Nursing, College, Metabolism, Movement, Peptide, The College of Medicine, Aesthetics, Longevity

CHANHASSEN, Minn., April 29, 2024 /PRNewswire/ -- Life Time (NYSE: LTH) today announced the appointment of James LaValle, clinical pharmacist, C.C.N.M.T. as Chief Science Officer. LaValle will spearhead the development and implementation of scientific initiatives and strategic relationships to support MIORA, Life Time's new longevity and performance program launched in late 2023, including the first dedicated MIORA clinic at Life Time Target Center in Minneapolis.

Key Points: 
  • CHANHASSEN, Minn., April 29, 2024 /PRNewswire/ -- Life Time (NYSE: LTH) today announced the appointment of James LaValle, clinical pharmacist, C.C.N.M.T.
  • as Chief Science Officer.
  • LaValle will spearhead the development and implementation of scientific initiatives and strategic relationships to support MIORA , Life Time's new longevity and performance program launched in late 2023, including the first dedicated MIORA clinic at Life Time Target Center in Minneapolis.
  • Building and enhancing new partnerships with the American Academy of Anti-Aging Medicine, International Peptide Society, and other leading organizations in the space.

Cannabis Market Flourishes Amid Global Legalization, Driving Concerns About Road Safety

Retrieved on: 
Monday, April 22, 2024
NGC, Financial News, Forensic Medicine Division, Medical laboratory, Workplace, Growth, Medical statistics, Legislation, Public opinion, Cannabinoid, Control, Pharmacokinetics, OTC, ACB, Chocolate, Cannabis, GACP, Edible, Curaleaf, Safety, THC, Certification, Health, Canopy Growth, Collection, Injury, Medical jurisprudence, Offense, IACT, CGC, Lord, Division, USD, University, Vital statistics, OTCQX, Tracking system, International Association, Patient, Principal, College, The College of Medicine, Drug

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Over the past decade, the cannabis market has undergone significant expansion, driven largely by a wave of legalization efforts across the United States and other parts of the world. As state and national governments reassess their legal stance on cannabis, both for medical and recreational use, the industry has seen a surge in legitimacy and economic interest. In the United States, a majority of states have legalized cannabis in some form, reflecting a shift in public opinion and an acknowledgement of the potential medical benefits and revenue generation opportunities. Globally, countries like Canada, Uruguay, and several European nations have moved towards more liberal cannabis policies, further propelling the market's growth. The financial implications of these legalization efforts are substantial and continue to evolve. According to a report by Grand View Research, the global legal cannabis market size was valued at USD 13.2 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 25.5% from 2022 to 2030. Cannabix Technologies Inc. (OTC: BLOZF) (CSE: BLO), Cronos Group Inc. (NASDAQ: CRON), Canopy Growth Corporation (NASDAQ: CGC), Aurora Cannabis Inc. (NASDAQ: ACB), Curaleaf Holdings, Inc. (OTC: CURLF)

Key Points: 
  • Globally, countries like Canada, Uruguay, and several European nations have moved towards more liberal cannabis policies, further propelling the market's growth.
  • One of the primary concerns is the correlation between cannabis use and impaired driving.
  • Studies have shown that cannabis can significantly impair motor coordination, reaction times, and decision making, which are critical skills for safe driving.
  • NGC also partners with Canadian GACP cultivators to produce and distribute finished cannabis products to both the domestic and global markets.

Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California

Retrieved on: 
Monday, April 22, 2024
University, Vital statistics, Safety, Pharmacokinetics, Tracking system, OTC, Forensic Medicine Division, Collection, Medical laboratory, Injury, Medical jurisprudence, International Association, Medical statistics, Principal, Legislation, College, IACT, Cannabinoid, The College of Medicine, Control, Division

VANCOUVER, British Columbia, April 22, 2024 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace reports that it will be presenting at the International Association for Chemical Testing (IACT) conference in April.

Key Points: 
  • VANCOUVER, British Columbia, April 22, 2024 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace reports that it will be presenting at the International Association for Chemical Testing (IACT) conference in April.
  • Cannabix’s Dr. Bruce Goldberger Ph.D., will be presenting on Science & Technology Behind Cannabis Breath Testing and the Company’s marijuana breathalyzer system at the conference workshop session.
  • IACT is composed of governmental agency personnel involved in chemical testing related to traffic safety.
  • IACT has standing committees to address various areas including legislation, training, new equipment and procedures and manufacturers of breath testing equipment.

AtlantiCare Announces VISION 2030--its Ambitious 6-Year Plan Advancing Systemwide Strategies and Bringing in Powerful New Partnerships to Transform Healthcare

Retrieved on: 
Wednesday, April 10, 2024
GNI, Patient, CDA, Safety, Health, Cardiology, Cleveland Clinic, MHL, Neuroscience, Elective surgery, Partnership, Research, Oracle, Human, Three-sector model, Senior, Multiple sclerosis, College, Drexel University, Caregiver, Workforce, The College of Medicine, Joint Commission, Longevity, Management

VISION 2030 also launches with the strength of several new partnerships including Oracle Health, representing a significant leap forward in AtlantiCare's digital transformation strategy.

Key Points: 
  • VISION 2030 also launches with the strength of several new partnerships including Oracle Health, representing a significant leap forward in AtlantiCare's digital transformation strategy.
  • AtlantiCare also announced that it is bringing world-renowned clinical excellence to the region through an affiliation with Cleveland Clinic Cancer Institute and a partnership with Global Neurosciences Institute.
  • VISION 2030 is focused on transforming the way healthcare is defined, measured and delivered nationwide.
  • As leader of the anchor institute in the region, he is committed to driving transformative change in how healthcare is delivered.

BDHEA Summit "Health Equity 2024: Charting Our Course" for Black Health March 4-5 in Washington

Retrieved on: 
Monday, March 4, 2024
College, InterContinental, Artificial intelligence, Health equity, Business Roundtable, EY, Health, Culture, Howard University, University, The College of Medicine, Consultant, Howard University Hospital, Health care, Organization, Patient, News, Kaiser Permanente, Bloomberg Philanthropies, Research, McKinsey & Company, Adventist HealthCare, Nursing

WASHINGTON, March 4, 2024 /PRNewswire/ -- Healthcare directors and CEOs will meet for a frank assessment of the state of Black health March 4 and 5 when the Black Directors Health Equity Agenda (BDHEA) convenes a Summit at the InterContinental Washington-The Wharf.

Key Points: 
  • Political headwinds, artificial intelligence, doctor shortages, lack of diverse representation and widening gaps in the social safety net are on the agenda for the BDHEA 2024 National Summit, "Health Equity 2024: Charting Our Course."
  • "The BDHEA Washington summit will bring together important voices to help direct transformative change within our respective organizations and communities."
  • "BDHEA has a mission to bring institutional firepower to the battle for better Black health," said Deborah Phillips, BDHEA executive director and founding member.
  • BDHEA also develops webinars and playbooks that address the impact of corporate board inclusion and governance on health equity.

Montefiore's Albert Einstein College of Medicine Announces Free Tuition in Perpetuity for All Medical School Students

Retrieved on: 
Monday, February 26, 2024
Barnard College, College, Physician, Albert Einstein, Montefiore Medical Center, Treatment, Learning disability, Teachers College, Columbia University, Drug, Child, The College of Medicine, Health, Evaluation, Trustee, Medicine, Columbia University, Science, Marilyn, Research, CERC, Student, Nursing

BRONX, N.Y., Feb. 26, 2024 /PRNewswire/ -- Dr. Philip Ozuah, President and CEO of Montefiore Einstein, the umbrella organization for Albert Einstein College of Medicine and Montefiore Health System, today announced that Albert Einstein College of Medicine has received a transformational gift from Ruth L. Gottesman, Ed.D., Chair of the Einstein Board of Trustees and Montefiore Health System board member. This historic gift – the largest made to any medical school in the country – will ensure that no student at Einstein will have to pay tuition again.

Key Points: 
  • This historic gift – the largest made to any medical school in the country – will ensure that no student at Einstein will have to pay tuition again.
  • With this donation, all current fourth-year students will be reimbursed their spring 2024 semester tuition and, effective beginning in August of this year, all students moving forward will receive free tuition at Albert Einstein College of Medicine.
  • Albert Einstein College of Medicine was founded in 1955 with a mission to welcome all students, without restrictions.
  • "Each year, well over 100 students enter Albert Einstein College of Medicine in their quest for degrees in medicine and science.

Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida

Retrieved on: 
Thursday, January 18, 2024
The College of Medicine, Notifiable disease, UCF, University, Immune tolerance, Research, State, Longevity, Antibody, College, Central Florida, Ageing, Immune system

CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with the University of Central Florida (UCF) to advance space medicine research.

Key Points: 
  • CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with the University of Central Florida (UCF) to advance space medicine research.
  • “If humanity is to become a spacefaring species, solving fundamental problems related to space travel and living are table-stakes.
  • The company will provide materials including candidates derived from its platform to support the collaborative research at UCF.
  • “UCF was born as a university to support the space program, and the College of Medicine is continuing that mission, working to bring back to Earth the secrets that space medicine research can reveal,” said Dr. Deborah German, vice president for health affairs and dean of UCF’s College of Medicine.

Baptist Health and FIU join forces to elevate care, address doctor shortage and boost medical research in South Florida

Retrieved on: 
Tuesday, November 28, 2023
Baptist Health South Florida, The College of Medicine, Research, Senior, Organization, Baptist Hospital, Health Affairs, Elective surgery, Radiation, College, FIU, Ecosystem, Teaching, System, Radiology, Florida International University, Physician, Baptist Health, College of Medicine, Health, Nursing, Baptists

Under the new enhanced affiliation with FIU, Baptist Hospital is on track to become a statutory teaching hospital with expanded undergraduate and graduate medical education programs, clinical research, and patient care.

Key Points: 
  • Under the new enhanced affiliation with FIU, Baptist Hospital is on track to become a statutory teaching hospital with expanded undergraduate and graduate medical education programs, clinical research, and patient care.
  • "This enhanced clinical and academic collaboration between Baptist Health and FIU's Herbert Wertheim College of Medicine will be transformative in reshaping healthcare in the region," said Baptist Health President and CEO Bo Boulenger.
  • "There is a great deal of excitement around this collaboration because it elevates the work both FIU and Baptist are doing," said FIU President Kenneth A. Jessell.
  • The two organizations have worked together for more than a decade to offer clinical rotations to medical students and an accredited medical residency program at Baptist Health West Kendall Baptist Hospital.

World-Renowned Scientist and Researcher Yaron Tomer, MD, named the Marilyn and Stanley M. Katz Dean at Einstein

Retrieved on: 
Friday, September 8, 2023
Diversity, equity, and inclusion, Albert Einstein, American Thyroid Association, Doctor of Education, College, Education, Icahn School of Medicine at Mount Sinai, The College of Medicine, Blue Ridge, COVID-19, Department of Medicine – University of Pamplona, Marilyn, Mount Sinai, Doctor of Philosophy, Associate, Science, Molecular medicine, Student, Social justice, Professor, MD, Division, Physician, Anita, Sheba Medical Center, Faculty, DEI, Growth, Albert Einstein College of Medicine, Environment, NIH, Social medicine, Nursing, Management, Montefiore, Endocrinology, Research

BRONX, N.Y., Sept. 8, 2023 /PRNewswire/ -- Yaron Tomer, MD, has been named the Marilyn and Stanley M. Katz Dean at the Albert Einstein College of Medicine , effective October 2nd, 2023.

Key Points: 
  • BRONX, N.Y., Sept. 8, 2023 /PRNewswire/ -- Yaron Tomer, MD, has been named the Marilyn and Stanley M. Katz Dean at the Albert Einstein College of Medicine , effective October 2nd, 2023.
  • As Dean, Dr. Tomer will lead this research-intensive medical school comprised of more than 1,900 full-time faculty to further advance its research, education, diversity, community engagement, and philanthropic missions.
  • Dr. Tomer will ensure Einstein continues its national leadership in biomedical research support, while offering one of the nation's largest programs for medical education.
  • His leadership will foster an environment that will prepare students and faculty to make lasting contributions to science."

EmVenio Research adds principal investigators to research team

Retrieved on: 
Tuesday, August 1, 2023
Vaccine, Emory University, Endometriosis, Bachelor of Science in Human Biology, College, Diabetes, Internal medicine, Youngstown, Ohio, The College of Medicine, Nephrology, American Board of Internal Medicine, MT, Chapel Hill, Medical school, Medical Association of Georgia, Youngstown State University, Research, Oregon Health & Science University, Medicine, Infection, Certification, Bachelor of Arts in Clinical Psychology, Chemistry, American Board of Commissioners for Foreign Missions, Alaska Federal Health Care Access Network, Kidney, Patient, University, Anemia, University of North Carolina School of Law, Northeast Ohio Medical University, Uterine fibroid, California Community College Athletic Association, Obstetrics, Knowledge, Pharmacology, Medical device, Nursing, Science, DRS

DURHAM, N.C., Aug. 1, 2023 /PRNewswire/ -- Clinical research organization EmVenio Research recently announced the addition of Dr. Stephen Blank, M.D., and Dr. Suzanne Swan, M.D., to its team, serving as principal investigators. In their roles, they will oversee and conduct objective clinical research to ensure independent, high quality and reproducible results, as well as manage oversight of compliance, financial, personnel and other related aspects of research projects. Coming from varying medical backgrounds, Dr. Blank and Dr. Swan offer a diversity of expertise, expanding EmVenio's ability to conduct a wider range of clinical trials.

Key Points: 
  • DURHAM, N.C., Aug. 1, 2023 /PRNewswire/ -- Clinical research organization EmVenio Research recently announced the addition of Dr. Stephen Blank, M.D., and Dr. Suzanne Swan, M.D., to its team, serving as principal investigators.
  • Stephen Blank and Suzanne Swan to its team of principal investigators.
  • Blank and Swan bring to our team a magnitude of experience and knowledge in the research of new treatments and therapies," said Thad Wolfram, EmVenio president.
  • "With their diverse backgrounds in medicine, they offer a unique level of oversight to the studies EmVenio conducts and provide our organization the depth to conduct a wider range of clinical research studies for pharmaceutical and clinical research organizations."